Practical aspects of the oral new anticoagulants
- 14 June 2011
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 86 (7) , 586-590
- https://doi.org/10.1002/ajh.22021
Abstract
After years of only oral vitamin K antagonists, there are new many new antithrombotic agents in development and on entering the marketplace. This review will analyze clinical trial results for these new agents—especially dibigatran, rivaroxaban, and apixiban. Also to be discussed are practical aspects of use of these new agents such monitoring, reversal, and use before procedures. Am. J. Hematol. 2011.Keywords
This publication has 34 references indexed in Scilit:
- Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and ApixabanClinical Journal of Sport Medicine, 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementNew England Journal of Medicine, 2010
- Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial FibrillationCirculation, 2010
- Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran EtexilateClinical Pharmacokinetics, 2010
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activityThrombosis and Haemostasis, 2010
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementNew England Journal of Medicine, 2009
- Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathyActa Neurochirurgica, 2008
- American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With CancerJournal of Clinical Oncology, 2007
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy VolunteersCirculation, 2002